Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Delvis Celdran

Neurology Port Saint Lucie, FL Medical Doctor

NPI 1780649541 CMS profile 308079

543 Nw Lake Whitney Pl, Unit 105, Port Saint Lucie, FL 34986

Open in the dashboard

General payments

$1,843

140 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Delvis Celdran of Port Saint Lucie, FL is reported in the CMS Open Payments database as having received $1,843 across 140 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $176 18
2024 General $296 15
2023 General $279 23
2022 General $15 1
2021 General $218 21
2020 General $233 18
2019 General $626 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Delvis Celdran
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Delvis Celdran were reported at $176. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Delvis Celdran Neurology median Middle half National median
2019 $626 $474 $118–$2,177 $163
2020 $233 $367 $82–$2,309 $114
2021 $218 $438 $104–$2,547 $132
2022 $15 $442 $103–$2,388 $149
2023 $279 $464 $119–$2,312 $160
2024 $296 $468 $119–$2,323 $164
2025 $176 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $763 69 payments
  2. AbbVie, Inc. $695 53 payments
  3. Genzyme Corporation $178 5 payments
  4. UCB, Inc. $48 2 payments
  5. Teva Pharmaceuticals USA, Inc. $40 2 payments
  6. Amgen Inc. $37 3 payments
  7. Allergan Inc. $27 2 payments
  8. EMD Serono, Inc. $25 2 payments
  9. TG Therapeutics, Inc. $17 1 payment
  10. Biogen, Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,830 139 payments
  2. Education $13 1 payment
Products named General payments · program years 2019–2025
  1. TROKENDI XR $727 65 payments
  2. UBRELVY Neuroscience $576 41 payments
  3. QULIPTA $445 35 payments
  4. LEMTRADA $159 3 payments
  5. Briviact $48 2 payments
  6. Austedo XR $40 2 payments
  7. AIMOVIG $37 3 payments
  8. OXTELLAR XR $36 4 payments
  9. UBRELVY Neuroscience $27 2 payments
  10. Mavenclad $25 2 payments
  11. Other $55 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 81 drugs

Part D claims

6,542

Median for Neurology: 833

Drug cost

$915,025

Median for Neurology: $202,670

Branded share of claims

18.6%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 11 $153,091
Aubagio Teriflunomide Brand 13 $121,301
Qulipta Atogepant Brand 91 $115,224
Nurtec Odt Rimegepant Sulfate Brand 47 $55,259
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 11 $54,135
Ubrelvy Ubrogepant Brand 34 $51,076
Nuedexta Dextromethorphan Hbr/Quinidine Brand 23 $35,335
Aimovig Autoinjector Erenumab-Aooe Brand 21 $35,312
Aptiom Eslicarbazepine Acetate Brand 22 $30,415
Briviact Brivaracetam Brand 17 $24,874

The 10 drugs with the highest cost, of 81 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$135,683

Medicare's payments for the services billed

Medicare patients

327

Average age 74

Services billed

1,147

190 women, 137 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 69%
Diabetes 54%
Depression 38%
Ischemic heart disease 36%
Alzheimer's or dementia 34%
Chronic kidney disease 26%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $139
$139 34 —
QULIPTA
  • AbbVie, Inc. $137
$137 91 —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

140 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record